


**REMARKS**

Applicants elect to prosecute claims 1-4, 15-17, 19, and 20, which the Action designates as the invention of Group I, and which the Action states are drawn to a KGF-2 polypeptide and a derivative, and a composition comprising the same. Applicants have cancelled claims 5-14 and 18 without prejudice or disclaimer; have amended claims 1, 15, 16, and 19; and have added new claim 21. Claim 1 has been amended so that it no longer encompasses subject matter recited in claim 1 of commonly-owned U.S. Patent No. 6,743,422, and claims 15, 16, and 19 have been amended so that they no longer depend from non-elected claims. No new matter has been added as a result of the above-described amendments. If Examiner Xie believes it to be helpful, the Examiner is invited to contact the undersigned representative by telephone at 312-913-0001.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff LLP**

Dated: December 1, 2005

By:   
Donald L. Zuhn, Jr., Ph.D.  
Reg. No. 48,710